What is Proov?
Founded by Dr. Amy Beckley and Ellen Schell, Proov operates at the forefront of the reproductive health industry. The company specializes in at-home hormone tracking, offering a proprietary diagnostic platform that empowers users to identify ovulation quality and luteal phase defects. By bridging the gap between clinical laboratory testing and consumer convenience, Proov has established a robust market position within the rapidly expanding FemTech ecosystem. The company's technology is designed to provide users with the clarity needed to navigate complex fertility journeys, effectively shifting the paradigm from reactive medical care to proactive, data-informed health management.
How much funding has Proov raised?
Proov has raised a total of $9.7M across 1 funding round:
Series A
$9.7M
Series A (2021): $9.7M with participation from SteelSky Ventures, Gingerbread Capital, Hambrecht Ducera Growth Ventures, Lightship Capital, Portfolia FemTech II Fund, and WCC Partners
Key Investors in Proov
SteelSky Ventures
SteelSky Ventures is a visionary venture fund focused on investing in companies that enhance access, care, and outcomes in women's health, supporting innovations across consumer and digital health.
Gingerbread Capital
Gingerbread Capital is dedicated to closing the funding gap for women-led ventures at early and growth stages, investing in exceptional founders across healthcare and consumer sectors.
Lightship Capital
Lightship Capital invests in remarkable founders and entrepreneurs who innovate in U.S. regions, focusing on developing talent and catalyzing emerging ecosystems to achieve significant returns.
What's next for Proov?
With this major enterprise-level funding, Proov is well-positioned to scale its operations and broaden its diagnostic capabilities. The strategic roadmap likely includes expanding its product suite to cover a wider spectrum of hormonal health markers, thereby increasing its utility for women across various life stages. Furthermore, the company is expected to leverage this capital to enhance its digital infrastructure, potentially integrating AI-driven analytics to provide more personalized health recommendations. As Proov continues to refine its market strategy, the focus will remain on scaling its distribution channels and solidifying its reputation as a leader in the home-based diagnostic space, ultimately aiming to improve health outcomes through accessible, high-quality data.
See full Proov company page
